CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Csl Innovation Pty Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Csl Innovation Pty Ltd
45 Poplar Road,Parkville
Phone: +61 392084000p:+61 392084000 Melbourne, NSW  3052  Australia Fax: +61 392084356f:+61 392084356
This company was Merged or Acquired on 10/31/2006.
This is a Subsidiary, click here for the Parent Company
Business Summary
Zenyth Therapeutics, Ltd. develops pharmaceutical and biotechnology products in the therapeutic areas of hematology, bladder cancer and anti-virals. The Company's core business is the research and development medicines to treat human diseases. Zenyth's in-house pharmaceutical R&D is focused on three key areas: infectious diseases, neurological disease, and allergy and inflammation. Its R&D activity targets the clinical development of compounds for serious chronic human diseases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20066/30/2006Yes----

Industries
SIC Code Description
7389 Business services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Andrew D.Nash 44 8/25/2005
Finance and Administration Director Alan M.Boyd 1/1/2002 1/1/2002
Company Secretary, General Counsel Robyn M.Fry 11/1/2000
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Amrad Corporation Limited
sAmrad Corporation Limited
Zenyth Therapeutics Limited

General Information
Number of Employees: 38 (As of 6/30/2006)
Outstanding Shares: 125,176,327 (As of 6/30/2006)
Shareholders: 5,790
Stock Exchange: ASX
Fax Number: +61 392084356


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023